contingency one tablet
mylan pharmaceuticals ulc - levonorgestrel - tablet - 1.5mg - levonorgestrel 1.5mg - contraceptives
microgestin norethindrone acetate and ethinyl estradiol tablet
actavis pharma, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 1 mg
lidocaine 4% cream
ennogen healthcare ltd - lidocaine - cutaneous cream - 40mg/1gram
tarina® fe 1/20 (norethindrone acetate and ethinyl estradiol tablets, usp and ferrous fumarate tablets)
rpk pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - tarina fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. adapted from ra hatcher et al, reference 7. * the authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason. ** this term represents “typical” couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use
tobramycin injection, usp solution
mylan pharmaceuticals ulc - tobramycin - solution - 40mg - tobramycin 40mg - aminoglycosides
idarubicin hydrochloride injection solution
mylan pharmaceuticals ulc - idarubicin hydrochloride - solution - 1mg - idarubicin hydrochloride 1mg - antineoplastic agents
gildess fe 1.5/30 norethindrone acetate ethinyl estradiol and ferrous fumarate
qualitest pharmaceuticals - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 1.5 mg
gildess fe 1/20 norethindrone acetate ethinyl estradiol and ferrous fumarate
qualitest pharmaceuticals - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 1 mg
gildess 1/20 norethindrone acetate and ethinyl estradiol tablet film coated
qualitest pharmaceuticals - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - norethindrone acetate 1 mg
blisovi fe 1.5/30- norethindrone acetate and ethinyl estradiol kit
lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - ethinyl estradiol 0.03 mg - blisovi fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. adapted from ra hatcher et al, reference 7. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - known or suspected carcinoma of the breast - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of